These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21235090)

  • 41. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
    Moulder SL
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 44. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

  • 45. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 46. HER-2-positive breast cancer: hope beyond trastuzumab.
    Bartsch R; Wenzel C; Zielinski CC; Steger GG
    BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Updates in anti-HER2 combination therapy.
    Burstein H
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):873-4. PubMed ID: 19209136
    [No Abstract]   [Full Text] [Related]  

  • 49. Trastuzumab in the adjuvant treatment of breast cancer.
    Svetlovska D; Mardiak J; Kristova V
    Bratisl Lek Listy; 2007; 108(2):100-3. PubMed ID: 17685010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Target therapy in HER2-overexpressing breast cancer patients.
    Amodio R; Zarcone M; Cusimano R; Campisi I; Dolcemascolo C; Traina A; Agostara B; Romano N
    OMICS; 2011 Jun; 15(6):363-7. PubMed ID: 21568729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trastuzumab: mechanisms of resistance and therapeutic opportunities.
    Calabrich A; Fernandes Gdos S; Katz A
    Oncology (Williston Park); 2008 Oct; 22(11):1250-8; discussion 1259, 1263. PubMed ID: 18980023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trastuzumab in breast cancer.
    Emens LA; Davidson NE
    Oncology (Williston Park); 2004 Aug; 18(9):1117-28; discussion 1131-2, 1137-8. PubMed ID: 15471197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The requirements to clinicopathology about targeted therapy for breast cancer].
    Jiang ZF; Shen G
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
    [No Abstract]   [Full Text] [Related]  

  • 54. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
    Dent R; Clemons M
    Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
    [No Abstract]   [Full Text] [Related]  

  • 55. [Monoclonal antibodies and breast cancer. Current therapeutic progress].
    Collignon J; Gennigens C; Rorive A; Coucke P; Lifrange E; Maweja S; Fillet G; Jerusalem G
    Rev Med Liege; 2009; 64(5-6):279-83. PubMed ID: 19642459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
    Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911
    [No Abstract]   [Full Text] [Related]  

  • 58. HER2-targeted therapies: how far we've come--and where we're headed.
    Davidson NE
    Oncology (Williston Park); 2011 Apr; 25(5):425-6. PubMed ID: 21710840
    [No Abstract]   [Full Text] [Related]  

  • 59. Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland.
    Ann Oncol; 2001; 12 Suppl 1():1-107. PubMed ID: 11816498
    [No Abstract]   [Full Text] [Related]  

  • 60. Experts debate value of HER2 testing methods.
    Nelson NJ
    J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.